OOIR: Observatory of International Research

Papers

(The TQCC of Cancer and Metastasis Reviews is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Editorial Expression of Concern: Targeting microRNAs as a promising anti-cancer therapeutic strategy against traffic-related air pollution-mediated lung cancer	159
Immunotherapy for leptomeningeal disease from solid tumors: current clinical outcomes and future opportunities	158
New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions	127
Of vascular defense, hemostasis, cancer, and platelet biology: an evolutionary perspective	94
The role of microbiome in pancreatic cancer	85
The impact of tumor microenvironment: unraveling the role of physical cues in breast cancer progression	79
The functions and modifications of tRNA-derived small RNAs in cancer biology	70
CAR T-cell therapy for B-cell lymphomas: outcomes and resistance mechanisms	66
Regulation of dormancy during tumor dissemination: the role of the ECM	61
Clonal tracking in cancer and metastasis	59
Obesity and cancer	57
Chemokines orchestrate tumor cells and the microenvironment to achieve metastatic heterogeneity	51
The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer	46
Immunotherapy for triple negative breast cancer: the end of the beginning or the beginning of the end?	46
Progression and metastasis of small cell lung carcinoma: the role of the PI3K/Akt/mTOR pathway and metabolic alterations	46
CAR T-cell therapy to treat multiple myeloma: current state and future directions	45
Targeting lipid metabolism in cancer: neuroblastoma	45
The paradoxical role of inositol in cancer: a consequence of the metabolic state of a tumor	42
Natural killer cells in neuroblastoma: immunological insights and therapeutic perspectives	42
Cell-cell interactions mediating primary and metastatic breast cancer dormancy	40
KISS1 metastasis suppressor in tumor dormancy: a potential therapeutic target for metastatic cancers?	40
TRIM-endous functional network of tripartite motif 29 (TRIM29) in cancer progression and beyond	39
Healthcare disparities, screening, and molecular testing in the changing landscape of non–small cell lung cancer in the United States: a review	35
Correction to: Cutting the edge between cancerogenesis and organogenesis of the pancreatic endocrine lineage allocation—comprehensive review of the genes Synaptotagmin 13 and 533041C22 Rik in epitheli	35
p73 isoforms meet evolution of metastasis	34

A multidisciplinary perspective on the complex interactions between sleep, circadian, and metabolic disruption in cancer patients	34
Preface	33
Biography—Mathieu Boissan, Pharm.D., Ph.D	33
Targeting microRNAs as a promising anti-cancer therapeutic strategy against traffic-related air pollution-mediated lung cancer	33
LGR5: An emerging therapeutic target for cancer metastasis and chemotherapy resistance	31
Neuropeptide Y in cancer—biological functions and potential clinical implications	31
Biographies	31
The role of cancer cell bioenergetics in dormancy and drug resistance	30
The multifaceted mechanisms of malignant glioblastoma progression and clinical implications	30
How circulating tumor cluster biology contributes to the metastatic cascade: from invasion to dissemination and dormancy	29
Biographies	29
Targeting DNA damage repair pathways in pancreas cancer	27
Cross-talk between the microbiome and chronic inflammation in esophageal cancer: potential driver of oncogenesis	27
Role of Neuropilin-2-mediated signaling axis in cancer progression and therapy resistance	26
Short-chain fatty acids in cancer pathogenesis	26
Tumor necrosis factor superfamily signaling: life and death in cancer	26
Clusterin: a marker and mediator of chemoresistance in colorectal cancer	25
Tissue-engineered patient-derived osteosarcoma models dissecting tumour-bone interactions	24
Immunomodulatory role of oncogenic alterations in non-small cell lung cancer: a review of implications for immunotherapy	24
Helicobacter pylori–activated fibroblasts as a silent partner in gastric cancer development	24
Systematic review of the receptor tyrosine kinase superfamily in neuroblastoma pathophysiology	24
Epigenetic reprogramming of T cells: unlocking new avenues for cancer immunotherapy	23
Impact of posttranslational modifications in pancreatic carcinogenesis and treatments	22
The tumor microenvironment in pancreatic ductal adenocarcinoma: current perspectives and future directions	22
Vaping and tumor metastasis: current insights and progress	22
Clinical interventions to break the obesity and cancer link: a narrative review	22
Carcinoma of unknown primary (CUP): an update for histopathologists	21
Functional and clinical roles of stromal PDGF receptors in tumor biology	21
The emerging roles of histone demethylases in cancers	21
The role of mitochondria in tumor metastasis and advances in mitochondria-targeted cancer therapy	20
Dormancy, stemness, and therapy resistance: interconnected players in cancer evolution	20
Kenneth V. Honn, Ph.D. (1946–2023)	20
Heterogeneity and tumor evolution reflected in liquid biopsy in metastatic breast cancer patients: a review	20
Debris-stimulated tumor growth: a Pandora’s box?	19
New progress of tuberculosis scar carcinoma	19
OX40/OX40 ligand and its role in precision immune oncology	19
Oncogenic functions of the FOXC2 transcription factor: a hallmarks of cancer perspective	19
Inflammatory bowel disease and carcinogenesis	19
Racial disparity in prostate cancer: an outlook in genetic and molecular landscape	19
HOXA9 transcription factor is a double-edged sword: from development to cancer progression	19
Ferroptosis: iron release mechanisms in the bioenergetic process	18
UCP2 and pancreatic cancer: conscious uncoupling for therapeutic effect	18
PRUNE1 and NME/NDPK family proteins influence energy metabolism and signaling in cancer metastases	18
The strict regulation of HIF-1α by non-coding RNAs: new insight towards proliferation, metastasis, and therapeutic resistance strategies	18
The plasticity of pancreatic cancer stem cells: implications in therapeutic resistance	17
CTGF (CCN2): a multifaceted mediator in breast cancer progression and therapeutic targeting	17
Recent advances in synthetic strategies and SAR of thiazolidin-4-one containing molecules in cancer therapeutics	16
Multifaceted role of the DNA replication protein MCM10 in maintaining genome stability and its implication in human diseases	16
Classification of anticancer drugs: an update with FDA- and EMA-approved drugs	16
Biographies	16

Is cancer an intelligent species?	16
Understanding metabolic alterations and heterogeneity in cancer progression through validated immunodetection of key molecular components: a case of carbonic anhydrase IX	16
Current state-of-the-art on ganglioside-mediated immune modulation in the tumor microenvironment	16